Two Sigma Investments
VVOS icon

Two Sigma Investments’s Vivos Therapeutics VVOS Stock Holding History

Two Sigma Investments’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,482
Closed -$53.5K – 3512
2024
Q3 		$53.5K Buy
+20,482
New +$53.6K ﹤0.01% 2966
2023
Q3 		– Sell
-2,532
Closed -$32.3K – 3242
2023
Q2 		$32.3K Sell
2,532
-1,109
-30% -$10.9K ﹤0.01% 2872
2023
Q1 		$31K Buy
+3,641
New +$79.6K ﹤0.01% 2811
2022
Q1 		– Sell
-4,689
Closed -$264K – 4415
2021
Q4 		$264K Sell
4,689
-1,604
-25% -$129K ﹤0.01% 3732
2021
Q3 		$636K Buy
+6,293
New +$661K ﹤0.01% 3029

Other funds holding VVOS

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments's VVOS Position: Q4 2024 in Review

Two Sigma Investments sold out of Vivos Therapeutics (VVOS) in Q4 2024, closing a stake of 20,482 shares — an estimated $53.5K sold.

Two Sigma Investments first reported a position in VVOS in Q3 2021 and held it in 5 quarters. The position peaked at $636K in Q3 2021. 20 funds tracked by Wall St. Rank hold VVOS as of Q4 2024.

  • Two Sigma Investments reported no remaining Vivos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Investments sold 20,482 Vivos Therapeutics shares in Q4 2024, an estimated $53.5K.
  • Two Sigma Investments first reported a position in Vivos Therapeutics in Q3 2021 and held it in 5 quarters.
  • Two Sigma Investments's Vivos Therapeutics position peaked at $636K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.